Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments
NCT03844412Phase 2Completed
- Sponsor
- Duke University
- Start
- Nov 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lidocaine 10% oropharyngeal spray, estradiol topical and nortriptyline in vestibulodynia (4 arms), sponsored by Duke University. Primary endpoints: Pain Score During the Tampon Test at 16 weeks, Change in Self-reported Pain Via the Short Form- McGill Pain Questionnaire at 16 weeks and 3 more. Started Nov 2019; status: completed.
02
Drugs
lidocaine 10% oropharyngeal sprayestradiol topicalnortriptyline
03
Conditions
vestibulodynia
Beyond the preview
Go deeper on NCT03844412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844412.